AdFalciVax Vaccine

AdFalciVax Vaccine Latest News

Recently, the Indian Council of Medical Research (ICMR) has granted non-exclusive rights for its multi-stage malaria vaccine, AdFalciVax, to five pharmaceutical companies.

About AdFalciVax Vaccine

• It is India’s first indigenous multi-stage malaria recombinant vaccine developed by the Regional Medical Research Centre (RMRC), Bhubaneswar, under the ICMR.

‹ ›

Key Feature of the Vaccine

• The vaccine is designed to prevent Plasmodium falciparum infection in individuals and reduce community transmission.
• Plasmodium falciparum is the deadliest malaria parasite, difficult to control and responsible for widespread devastation
• AdFalciVax targets the parasite before it enters the bloodstream, stopping the infection at the transmission stage
• The vaccine uses Lactococcus lactis, a genetically engineered food-grade bacterial host, as its core technology
• It delivers a dual-antigen approach combining: PfCSP (Plasmodium falciparum circumsporozoite protein) to prevent infection and Pfs230 and Pfs48/45 fusion proteins to block transmission from humans to mosquitoes
• This dual-antigen approach makes AdFalciVax a multi-functional vaccine, aimed at both protecting individuals and halting the spread of malaria.
• Pre-clinical validation was carried out in collaboration with  ICMR–National Institute of Malaria Research (ICMR-NIMR)and National Institute of Immunology (NII), Delhi, under the Department of Biotechnology.

Source: BS